Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 1
2013 3
2014 2
2015 3
2016 7
2017 6
2018 10
2019 17
2020 17
2021 15
2022 5
2023 11
2024 11

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30793734

101 results

Results by year

Filters applied: . Clear all
Page 1
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Oldgren J, et al. Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059. Eur Heart J. 2019. PMID: 30793734 Free PMC article. Clinical Trial.
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Ten Berg JM, et al. Am J Cardiol. 2020 Mar 1;125(5):735-743. doi: 10.1016/j.amjcard.2019.11.029. Epub 2019 Dec 9. Am J Cardiol. 2020. PMID: 31924322 Free article.
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
De Caterina R, Procopio A, Lopez Sendon JL, Raev D, Mehta SR, Opolski G, Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Kleine E, Ten Berg JM, Bhatt DL, Miede C, Nordaby M, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. De Caterina R, et al. Am J Med. 2020 Nov;133(11):1302-1312. doi: 10.1016/j.amjmed.2020.03.045. Epub 2020 May 7. Am J Med. 2020. PMID: 32389658 Free article. Clinical Trial.
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. Berry NC, et al. Circ Cardiovasc Interv. 2020 Apr;13(4):e008349. doi: 10.1161/CIRCINTERVENTIONS.119.008349. Epub 2020 Apr 7. Circ Cardiovasc Interv. 2020. PMID: 32252548 Free article. Clinical Trial.
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Cannon CP, et al. Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26. Clin Cardiol. 2016. PMID: 27565018 Free PMC article. Clinical Trial.
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Cannon CP, et al. N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844193 Free article. Clinical Trial.
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Ten Berg JM, et al. JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039. JACC Cardiovasc Interv. 2019. PMID: 31806214 Free article. Clinical Trial.
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Maeng M, et al. JACC Cardiovasc Interv. 2019 Dec 9;12(23):2346-2355. doi: 10.1016/j.jcin.2019.07.059. JACC Cardiovasc Interv. 2019. PMID: 31806216 Free article. Clinical Trial.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. Lip GYH, et al. Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1. Am Heart J. 2019. PMID: 30928824 Clinical Trial.
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Nicolau JC, et al. Drugs. 2020 Jul;80(10):995-1005. doi: 10.1007/s40265-020-01323-x. Drugs. 2020. PMID: 32562206 Free PMC article. Clinical Trial.
101 results